Sometimes it starts with a sharp pain in your knees when you get out of bed in the morning…
Or agony in your hip as you walk down the stairs… Or even stiffness in your fingers after working on the car.
But no matter how it begins, it almost always ends the same: Worsening pain, and a diagnosis of a disorder that, currently, has slim treatment options.
We’re talking about osteoarthritis.
If you’re not familiar with the name now, you may be in the future. Osteoarthritis is affecting younger and younger crowds, and already lessens the quality of life for nearly 30 million Americans.
And, up until very recently, the treatment options consisted of nerve-damaging steroids or potentially addictive opioids.
Thankfully, one company may have found the best possible solution to the osteoarthritis problem,
Not only is their newest drug opioid-free and steroid-free, but it also is poised for a potential 58,213% revenue surge…
This Could Be a Life-Changing Drug
Osteoarthritis is the most common form of arthritis, nicknamed “wear and tear” arthritis.
Often incited by old injuries or genetics, osteoarthritis is associated with a breakdown of cartilage between joints.
Cartilage is the firm, rubbery barrier between joints that acts as a shock absorber, allowing you to move your joints with ease. But with this “wear and tear” arthritis, cartilage breaks down and causes excruciating pain for its sufferers as bone begins to grind against bone.
And up until now, the only treatments have been harmful steroids or opioids.
But one company is about to change the game.
By utilizing a unique “microsphere” technology, the company championing this drug has been able to virtually eliminate the need for steroids or opioids in tandem.
The microspheres measure half the length of a human hair, and a mere 0.0064 of a teaspoon of these microspheres are on the road to ending debilitating osteoarthritis pain indefinitely.
It’s not every day that you hear of a new drug with as much potential as the one we’re talking about today.
But, similar situations have occurred before. And savvy investors who staked their claim early saw some extraordinary gains…
Take Pfizer (NYSE:PFE), for instance. It was a $1 stock before their blockbuster Lipitor hit the market. Then after FDA approval, it shot up 1,735%.
Same with GlaxoSmithKline plc (NYSE:GSK) – it was a tiny $1 stock. Then it shot up 3,700% after the FDA approval of their drug, Advair.
We saw it again with Celgene Corp. (NasdaqGS:CELG). It was trading for $4.30 before Revlimid was approved. Afterward, the stock shot up 2,924%.
But this microsphere treatment could be the biggest blockbuster of them all. With FDA approval expected, we estimate a small stake could turn into $1,494,800.
The only catch is we expect that announcement to come any day now.
So time is running out.
The Wall Street Insights & Indictments Research Team